Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)
Preclinical data demonstrate tumor response with AVA6103 in the setting of Enhertu®-resistance
Covered in this story
Call it yourself
No calls on $AVA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Avista Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.